{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"Percentage of participants with complete response (CR) or partial response (PR) as per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.0 (Therasse et al. Natl Cancer Inst 92 (2000) pp205-216).","groups":[{"description":"AZD4877 25 mg (Intravenous (IV), 25mg weekly)","id":"OG000","title":"AZD4877"}],"paramType":"NUMBER","populationDescription":"Of the 41 participants who received at least one dose of study medication, only 39 were evaluable for response by RECIST (excludes 2 patients who had baseline scans performed more than 28 days before dosing).","reportingStatus":"POSTED","timeFrame":"8 weeks after study drug begins & and every 8 wks thereafter until discontinuation of study drug ( maximum treatment period of 309 days (44 weeks)","title":"Objective Response Rate (ORR) as Evaluated by Response Evaluation Criteria In Solid Tumors (RECIST)","type":"PRIMARY","unitOfMeasure":"Percengate of participants"}